Objective: A scoping review was conducted to screen the published literature on the clinical, financial, and educational effect of postgraduate second year (PGY2) pharmacy residency training.
Findings: A search strategy was conducted in MEDLINE, EMBASE, CINAHL, Cochrane Central and Web of Science without study design, language, or time restrictions (inception to March 2022). Articles were reported using the PRISMA reporting items list. Studies were included if a measurable clinical outcome, a cost-avoidance calculation and/or involvement in teaching or research activities was reported. Studies were excluded if there was no mention of a PGY2 training. Of the 2534 articles that were screened, 21 articles met our inclusion criteria. Seven studies reported clinical outcomes, five reported cost avoidance, six reported educational outcomes and three studies reported both clinical and cost-avoidance outcomes. Four of the studies evaluating clinical outcomes took place in a psychiatric clinic setting. Better disease control was reported in four articles. Two studies evaluated readmission and emergency department visits at 30 days but only one showed significant reduction. The estimated cost avoidance reported ranged from $22,380 to $5,387,679 and two studies reported the services billed by the resident. In two studies, PGY2 pharmacists were more likely to be involved in teaching activities and were more likely to participate in research activities.
Conclusion: Even though few studies evaluated the benefits of PGY2 pharmacy trainings, they showed to improve patient care, enhance involvement in teaching activities, and decrease financial burden for health-care systems. More studies should be done to reinforce the merits of such training.
Keywords: PGY2; Postgraduate second-year residency; Scoping review; Specialized pharmacist; Specialized residency.
Copyright © 2023 American Association of Colleges of Pharmacy. Published by Elsevier Inc. All rights reserved.